Atossa Therapeutics, Inc. income statement

In fiscal 2015, Atossa Therapeutics, Inc. reported revenue of $1,758, down 95.6% on the year before, operating income of −$12.8m (a -725746.2% margin) and net income of −$15.8m, or −$124.65 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atossa Therapeutics, Inc.: income statement, annual
Fiscal year	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	LTMSept 2016
Revenue	0	0	1	0	0	0
Cost of revenue	0	0	0	0	0	—
Gross profit	−0	0	0	0	−0	—
Research and development	—	2	1	1	2	1
General and administrative	3	3	9	8	9	7
Operating income	−3	−5	−11	−12	−13	−8
Interest expense	0	0	0	0	—	—
Income before tax	−3	−5	−11	−12	−13	−6
Income tax	0	0	0	0	0	0
Net income	−3	−5	−11	−15	−16	−9
Diluted EPS	−$85.50	−$0.41	−$0.70	−$0.61	−$124.65	—
Diluted shares (average)	—	—	—	—	—	—
EBITDA	−3	−5	−10	−12	−12	−8

US$ thousands unless shown otherwise. Fiscal quarters.

Atossa Therapeutics, Inc.: income statement, quarterly
Quarter	2014 Q4Dec 2014	2015 Q1Mar 2015	2015 Q2Jun 2015	2015 Q3Sept 2015	2015 Q4Dec 2015	2016 Q1Mar 2016	2016 Q2Jun 2016	2016 Q3Sept 2016
Revenue	3	0	0	0	2	0	0	0
Cost of revenue	0	0	0	313	−3,244	0	0	—
Gross profit	3	0	0	459	−2,094	0	0	—
Research and development	−746	566	373	949	471	150	169	85
General and administrative	1,772	2,361	2,454	2,395	1,638	2,178	1,553	1,473
Operating income	−3,328	−3,273	−3,171	−3,843	−2,474	−2,328	−1,722	−1,558
Interest expense	13	2	—	—	—	—	—	—
Income before tax	−3,326	−3,274	−3,122	−3,773	−2,590	−2,328	−1,722	205
Income tax	0	0	0	0	0	0	0	0
Net income	−5,813	−3,335	−3,145	−4,318	−4,962	−2,328	−1,722	205
Diluted EPS	−$0.24	−$0.13	−$0.11	−$0.15	−$118.80	−$176.40	−$120.60	$12.60
EBITDA	−3,229	−3,208	−3,157	−3,810	−2,370	−2,252	−1,690	−1,529

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atossa Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atossa Therapeutics, Inc.